PDE2 at the crossway between cAMP and cGMP signalling in the heart

2017 | journal article; overview

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​PDE2 at the crossway between cAMP and cGMP signalling in the heart​
Weber, S.; Zeller, M.; Guan, K. ; Wunder, F.; Wagner, M. & El-Armouche, A. ​ (2017) 
Cellular Signalling38 pp. 76​-84​.​ DOI: https://doi.org/10.1016/j.cellsig.2017.06.020 

Documents & Media

License

GRO License GRO License

Details

Authors
Weber, Silvio; Zeller, Miriam; Guan, Kaomei ; Wunder, Frank; Wagner, Michael; El-Armouche, Ali 
Abstract
The cyclic nucleotides cAMP and cGMP are central second messengers in cardiac cells and critical regulators of cardiac physiology as well as pathophysiology. Consequently, subcellular compartmentalization allows for spatiotemporal control of cAMP/cGMP metabolism and subsequent regulation of their respective effector kinases PKA or PKG is most important for cardiac function in health and disease. While acute cAMP-mediated signalling is a mandatory prerequisite for the physiological fight-or-flight response and enhanced cardiac contractility and relaxation, sustained activation of this pathway may lead to the progression of heart failure. In contrast, acute as well as sustained cGMP-mediated signalling can foster beneficial features, e.g. anti-hypertrophic and vasodilatory effects and thus blunting some of the aforementioned cAMP-mediated effects. Although these two signalling pathways seem to be intuitively counteracting, there is increasing evidence for a functionally relevant crosstalk between cAMP and cGMP signalling pathways on the level of cyclic nucleotide hydrolysing phosphodiesterases (PDEs). Among this diverse group of enzymes, PDE2 fulfils a unique integrator role. Equipped with dual substrate specificity for cAMP as well as for cGMP, it is the only cAMP hydrolysing PDE, which is allosterically activated by cGMP. Recent studies have revealed strongly remodelled cAMP/cGMP microdomains and subcellular concentration profiles in different cardiac pathologies, leading to a putatively enhanced involvement of PDE2 in cAMP/cGMP breakdown and crosstalk compared to the other cardiac PDEs. This review sums up the current knowledge about molecular properties and regulation of PDE2 and explains the complex signalling network encompassing PDE2 in order to better understand the functional role of PDE2 in distinct cell types in cardiac health and disease. Moreover, this review gives an outlook in which way PDE2 may serve as a therapeutic target to treat cardiac diseases.
Issue Date
2017
Journal
Cellular Signalling 
Project
SFB 1002: Modulatorische Einheiten bei Herzinsuffizienz 
SFB 1002 | A02: Bedeutung des Phosphatase-Inhibitors-1 für die SR-spezifische Modulation der Beta- adrenozeptor-Signalkaskade 
Working Group
RG El-Armouche 
RG Guan (Application of patient-specific induced pluripotent stem cells in disease modelling) 
ISSN
1873-3913
Language
English

Reference

Citations


Social Media